A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects.
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2014
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ADAGIO
- Sponsors Teva Pharmaceutical Industries
- 20 Jun 2013 A post-hoc analysis will be presented at the 17th Annual International Congress of Parkinson's Disease and Movement Disorders, according to a Teva media release.
- 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
- 20 Apr 2010 Results from a placebo group substudy reported at AAN 2010, according to a Teva Pharmaceutical media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History